Ferring's fecal transplant on brink of milestone approval

23 September 2022

Privately-held Swiss company Ferring Pharmaceuticals and its subsidiary Rebiotix look set to achieve a notable first for the industry.

Their investigational microbiota-based live biotherapeutic RBX2660 - also known as Rebyota - is on the brink of becoming the first microbiome-based therapy to gain a regulatory approval.

Ferring is seeking US Food and Drug Administration (FDA) approval for this fecal microbiota suspension - which is prepared from human stool collected from pre-screened, qualified donors and administered rectally by enema - to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK